IV Linezolid Dosing: Frequency and Duration
For adults, administer linezolid 600 mg IV every 12 hours; for children <12 years, use 10 mg/kg IV every 8 hours (maximum 600 mg/dose). Treatment duration is infection-specific, ranging from 7-21 days for pneumonia to ≥8 weeks for osteomyelitis 1, 2, 3.
Dosing Frequency by Age
Adults and Children ≥12 Years
- Standard dose: 600 mg IV every 12 hours 1, 2, 3
- This applies to all indications including complicated skin/soft tissue infections, pneumonia, bacteremia, and bone/joint infections
Children <12 Years
- Standard dose: 10 mg/kg IV every 8 hours, not to exceed 600 mg/dose 1, 2, 3
- Note the critical difference: pediatric dosing is every 8 hours (three times daily), not every 12 hours
Treatment Duration by Indication
Skin and Soft Tissue Infections
Pneumonia (MRSA)
- Duration: 7-21 days depending on severity and clinical response 1, 2, 4
- For hospital-acquired or ventilator-associated pneumonia, treatment typically extends toward the longer end of this range
Bacteremia
- Uncomplicated: Minimum 2 weeks 1
- Complicated: 4-6 weeks depending on extent of infection 1
- Uncomplicated bacteremia requires: catheter removal (if catheter-related), negative blood cultures 2-4 days after initial positive set, defervescence within 72 hours, and no metastatic infection sites
Bone and Joint Infections
- Osteomyelitis: Minimum 8 weeks, potentially extending to 3-6 months for chronic infection 1, 2
- Septic arthritis: 3-4 weeks 4
- Surgical debridement is the mainstay of therapy and should be performed whenever feasible
Central Nervous System Infections
Critical Safety Considerations
Thrombocytopenia Risk
Monitor complete blood counts weekly for treatment >14 days 3, 5. Thrombocytopenia is duration-dependent, occurring more frequently with treatment exceeding 2 weeks 3, 5. In clinical trials, 2.4% of linezolid-treated patients developed substantially low platelet counts (<75% of lower limit of normal) versus 1.5% with comparators 3.
The risk is particularly elevated in:
If thrombocytopenia develops: Consider dose reduction or temporary discontinuation. Recent evidence suggests therapeutic drug monitoring can guide individualized dosing to maintain efficacy while minimizing toxicity 6.
Renal Impairment Dosing
While the FDA label does not mandate dose adjustment for renal impairment 3, emerging evidence suggests modified regimens may improve safety:
- Severe renal impairment: Consider 300 mg every 12 hours 7
- Moderate renal impairment: Consider 450 mg every 12 hours 7
- Normal or mild impairment: Standard 600 mg every 12 hours 7
Alternative Infusion Strategies
Recent research suggests continuous infusion (600 mg loading dose, then 1200 mg/day continuous infusion) may improve clinical outcomes and reduce thrombocytopenia risk in critically ill patients 8, 9. However, this approach is not yet reflected in official guidelines and requires careful consideration of toxicity thresholds (maintain trough <8 mg/L) 10.
Common Pitfalls to Avoid
Pediatric dosing error: Do not use adult every-12-hour dosing in children <12 years—they require every-8-hour dosing 1, 2
Inadequate monitoring: Failing to obtain weekly CBC for treatment >14 days increases risk of undetected myelosuppression 3, 5
Premature discontinuation in osteomyelitis: The minimum 8-week duration is critical; shorter courses risk treatment failure 1, 2
Ignoring drug interactions: Linezolid is a weak, reversible MAO inhibitor—avoid tyramine-rich foods and use caution with serotonergic agents 3, 5
Overlooking therapeutic drug monitoring: For prolonged therapy (>2 weeks) or in patients with renal impairment, TDM can optimize dosing and prevent toxicity 6
The evidence consistently supports twice-daily dosing in adults based on pharmacokinetic studies demonstrating linear kinetics and concentrations remaining above MIC90 for most of the 12-hour dosing interval 11. The three-times-daily pediatric dosing reflects different pharmacokinetic parameters in younger children 12, 3.